The Role of Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma


A select group of hematologic oncologists participated in a virtual workshop to discuss the role of BTK inhibitors in the treatment of MCL and CLL Led by Kami Maddocks, MD; and Anthony Mato, MD. The expert panel shared insights on the available evidence regarding BTK inhibitors in MCL and CLL, novel treatment approaches, and optimal strategies for combining and sequencing therapies.

Related Videos
Tycel Phillips, MD, MPH
Pallawi Torka, MD
Carolyn Owen, MD, FRCPC
Alexey V. Danilov, MD, PhD
Kami J. Maddocks, MD
Matthew A. Lunning, DO, FACP
Anita Kumar, MD
Sarah Sammons, MD
Laura Spring, MD
Related Content